We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ergomed Plc | LSE:ERGO | London | Ordinary Share | GB00BN7ZCY67 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,346.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMERGO
RNS Number : 8274P
Ergomed plc
13 February 2019
PRESS RELEASE
FOR IMMEDIATE RELEASE
Proposed Board and Management Changes
Guildford, UK - 13 February 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that Stuart Jackson, Chief Financial Officer and Board Director has indicated that he will leave the Company in the Summer of 2019 to take up a position as Chief Financial Officer of a listed entity, returning to the energy sector.
Stuart will continue as a Board Director and Chief Financial Officer of Ergomed PLC until a replacement has been secured in order to ensure a smooth transition process. A search for his replacement is underway and the Company will provide an update on his successor in due course.
Dr Miroslav Reljanovic, Executive Chairman of Ergomed, said: "I would like to thank Stuart for his support and contribution to Ergomed. In the time he has been with us, he has made a positive impact on the business and has strengthened our finance and reporting capabilities. I look forward to continuing to work closely with him over the coming months whilst we select his successor. We wish Stuart every success in his new role."
- Ends -
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975 Miroslav Reljanovic (Executive Chairman) Stuart Jackson (Chief Financial Officer) Numis Securities Limited Tel: +44 (0) 20 7260 1000 Michael Meade / Freddie Barnfield (Nominated Adviser) James Black (Joint Broker) Consilium Strategic Communications - for Tel: +44 (0) 20 3709 5700 UK enquiries Chris Gardner / Mary-Jane Elliott ergomed@consilium-comms.com Matthew Neal / Olivia Manser MC Services - for Continental European enquiries Tel: +49 211 5292 5222 Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
BOAGGUAWPUPBPGP
(END) Dow Jones Newswires
February 13, 2019 02:00 ET (07:00 GMT)
1 Year Ergomed Chart |
1 Month Ergomed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions